Bispecific T Cell-Engager Assay

Limited T cell infiltration of tumour sites remain a major issue in oncological immunotherapies, preventing the effective targeting of cancer cells. To overcome this obstacle, Bispecific T Cell-Engager antibodies were designed to simultaneously bind to CD3 expressing T-cells and specific antigens on target tumour cells, redirecting the T cells to the tumour site and increasing the anti tumour activity of the immune system. At Cellomatics, our vast experience of handling a variety of immortalised and primary cancer cell lines as well as immune cells allows us to provide a customisable and physiologicall relevant assays to gain insight into the bispecific antibody specificity, target engagement and binding affinities.